Share This Article:

The Effectiveness of Glyburide Compared to Insulin in the Management of Gestational Diabetes Mellitus: A Systematic Review

Abstract Full-Text HTML XML Download Download as PDF (Size:3071KB) PP. 58-66
DOI: 10.4236/jdm.2015.52007    2,829 Downloads   3,501 Views   Citations

ABSTRACT

Background: Insulin therapy has been the mainstay in managing women with gestational diabetes mellitus (GDM), but some disadvantages of insulin have led to the use of glyburide, which is inexpensive in some countries, to manage GDM. However, there has been debate over its effectiveness, efficacy and safety when compared to insulin for maternal glycaemic control, and some adverse neonatal outcomes in GDM. Method: A systematic review of eight randomised controlled trial (RCT) studies was undertaken to compare glyburide and insulin. Studies involving 849 participants were included in the quantitative analysis. Results: There was no significant difference between glyburide and insulin in maternal fasting (P = 0.09; SMD: 0.13; 95% CI: 0.02 to 0.28) and postprandial (P = 0.45; SMD: 0.05; 95% CI: 0.09 to 0.19) glycaemic control and glycosylated hae-moglobin (P = 0.35; SMD: 0.08; 95% CI: 0.08 to 0.24). When compared with insulin, glyburide had an increase risk ratio (RR) for neonatal hypoglycaemia (P = 0.0002; RR: 2.27; 95% CI: 1.47 to 3.51) and large for gestational age babies (P = 0.03; RR: 1.60; 95% CI: 1.06 to 2.41). Estimation of standard mean difference shows that neonatal birth weight was significantly higher in subjects receiving glyburide than in the insulin group (P = 0.002; SMD: 0.21; 95% CI: 0.08 to 0.35). Conclusions: Glyburide was seen to be clinically effective and a safer alternative to insulin for maternal glycaemic control in GDM women. It is affordable, convenient and requires no comprehensive educative training at the time of initiation of therapy. However, its adverse outcomes—neonatal hypogly-caemia, high neonatal birth weight and large for gestational age babies—call for careful monitoring of GDM patients for any need for supplemental insulin.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Odiba, J. and Mabhala, M. (2015) The Effectiveness of Glyburide Compared to Insulin in the Management of Gestational Diabetes Mellitus: A Systematic Review. Journal of Diabetes Mellitus, 5, 58-66. doi: 10.4236/jdm.2015.52007.

References

[1] Veeraswamy, S., Vijayam, B., Gupta, V.K. and Kapur, A. (2012) The Public Health Relevance and Approach. Diabetes Research and Clinical Practice, 97, 350-358.
http://dx.doi.org/10.1016/j.diabres.2012.04.024
[2] United Nations (2014) We Can end Poverty: Millennium Development Goals and beyond 2015.
http://www.un.org/millenniumgoals/
[3] Rotheram-Borus, M.J., Tomlinson, M., Swendeman, D., Lee, A. and Jones, E. (2012) Standardized Functions for Smartphone Applications: Examples from Maternal and Child Health. International Journal of Telemedicine Applications, 1, 21-21.
[4] Dhulkotia, J.S., Bolarinde, O., Fraser, R. and Farrell, T. (2010) Oral Hypoglycaemic Agent’s vs Insulin in Management of Gestational Diabetes: A Systematic Review and Meta-Analysis. American Journal of Obstetrics and Gynaecology, 203, 1-9.
[5] Langer, O., Conway, D.L., Berkus, M.D., Xenakis, E.M.-J. and Gonzales, O. (2000) A Comparison of Glyburide and Insulin in Women with Gestational Diabetes Mellitus. New England Journal of Medicine, 343, 1134-1138.
[6] Bertini, A.M., Silva, J.C., Taborda, W., Becker, F., Bebber, F.R.L., Viesi, J.M.Z., Aquim, G. and Ribeiro, T.E. (2005) Perinatal Outcomes and the Use of Oral Hypoglycaemic Agents. Journal of Perinatal Medicine, 33, 519-523. http://dx.doi.org/10.1515/JPM.2005.092
[7] Goetzl, L. and Wilkins, I. (2002) Glyburide Compared to Insulin for the Treatment of Gestational Diabetes Mellitus: A Cost Analysis. Perinatology, 22, 403-406.
http://dx.doi.org/10.1038/sj.jp.7210759
[8] Altman, D.G., Schulz, K.F. and Moher, D. (2001) The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. Annals of Internal Medicine, 134, 663-694.
http://dx.doi.org/10.7326/0003-4819-134-8-200104170-00012
[9] Centre for Reviews and Dissemination (2009) Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf
[10] Higgins, J. and Green, S. (2011) Cochrane Handbook for Systematic Review of Interventions Version 20 5.1.0 11. http://handbook.cochrane.org/
[11] Anjalakshi, C., Balaji, V., Balaji, M.S. and Seshiah, V. (2007) A Prospective Study Comparing Insulin and Glibenclamide in Gestational Diabetes Mellitus in Asian Indian Women. Diabetes Research and Clinical Practice, 76, 474-475. http://dx.doi.org/10.1016/j.diabres.2006.09.031
[12] Silva, J.C., Bertini, A.M., Taborda, W., Becker, F., Bebber, F.R., Aquim, G.M. and Viesi, J.M. (2007) Glibenclamide in the Treatment for Gestational Diabetes Mellitus in a Compared Study to Insulin. Archives of Endocrinology and Metabolism, 51, 541-546.
[13] Ogunyemi, D., Jesse, M. and Davidson, M. (2007) Comparison of Glyburide versus Insulin in Management of Gestational Diabetes Mellitus. Endocrinology Practice, 13, 427-428.
http://dx.doi.org/10.4158/EP.13.4.427
[14] Lain, K.Y., Garabedian, M.J., Daftary, A. and Jeyabalan, A. (2009) Neonatal Adiposity Following Maternal Treatment of Gestational Diabetes with Glyburide Compared with Insulin. American Journal of Obstetrics and Gynaecology, 200, e1-e6.
[15] Mukhopadhyay, P., Sankar, T.B., Kyal, A. and Saha, P.D. (2012) Oral Hypoglyceamic Glibenclamide: Can It Be a Substitute to Insulin in the Management of Gestational Diabetes Mellitus? A Comparative Study. Journal of South Asian Federation of Obstetrics and Gynaecology, 4, 28-31.
http://dx.doi.org/10.5005/jp-journals-10006-1167
[16] Anjali, T. and Mayanglambam, R.D. (2013) Glyburide as Treatment Option for Gestational Diabetes Mellitus. Journal of Obstetrics and Gynaecology Research, 39, 1147-1152.
[17] Esposito, K., Giugliano, D., Nappo, F. and Marfella, R., Campanian Postprandial Hyperglycemia Study Group (2004) Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycaemia in Type 2 Diabetes Mellitus. Circulation, 110, 214-219.
http://dx.doi.org/10.1161/01.CIR.0000134501.57864.66
[18] Kremer, C.J. and Duff, P. (2004) Glyburide for the Treatment of Gestational Diabetes. American Journal of Obstetrics and Gynaecology, 190, 1438-1439.
http://dx.doi.org/10.1016/j.ajog.2004.02.032
[19] Chmait, R., Dinise, T. and Moore, T. (2004) Prospective Observational Study to Establish Predictors of Glyburide Success in Women with Gestational Diabetes Mellitus. Journal for Perinatology, 24, 617-622. http://dx.doi.org/10.1038/sj.jp.7211147
[20] Chang, L.-C., Liu, C.-H. and Yen, E.H.-W. (2012) Treatment of Gestational Diabetes Mellitus: Glyburide Compare to Subcutaneous Insulin Therapy and Associated Perinatal Outcomes. Journal of Maternal-Fetal and Neonatal Medicine, 25, 379-384.
http://dx.doi.org/10.3109/14767058.2011.580402

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.